Literature DB >> 34282852

Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment.

Jenny McCleery1, Julian Laverty2, Terry J Quinn3.   

Abstract

BACKGROUND: Many millions of people living with dementia around the world are not diagnosed, which has a negative impact both on their access to care and treatment and on rational service planning. Telehealth - the use of information and communication technology (ICT) to provide health services at a distance - may be a way to increase access to specialist assessment for people with suspected dementia, especially those living in remote or rural areas. It has also been much used during the COVID-19 pandemic. It is important to know whether diagnoses made using telehealth assessment are as accurate as those made in conventional, face-to-face clinical settings.
OBJECTIVES: Primary objective: to assess the diagnostic accuracy of telehealth assessment for dementia and mild cognitive impairment. Secondary objectives: to identify the quality and quantity of the relevant research evidence; to identify sources of heterogeneity in the test accuracy data; to identify and synthesise any data on patient or clinician satisfaction, resource use, costs or feasibility of the telehealth assessment models in the included studies. SEARCH
METHODS: We searched multiple databases and clinical trial registers on 4 November 2020 for published and 'grey' literature and registered trials. We applied no search filters and no language restrictions. We screened the retrieved citations in duplicate and assessed in duplicate the full texts of papers considered potentially relevant. SELECTION CRITERIA: We included in the review cross-sectional studies with 10 or more participants who had been referred to a specialist service for assessment of a suspected cognitive disorder. Within a period of one month or less, each participant had to undergo two clinical assessments designed to diagnose dementia or mild cognitive impairment (MCI): a telehealth assessment (the index test) and a conventional face-to-face assessment (the reference standard). The telehealth assessment could be informed by some data collected face-to-face, e.g. by nurses working in primary care, but all contact between the patient and the specialist clinician responsible for synthesising the information and making the diagnosis had to take place remotely using ICT. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data from included studies. Data extracted covered study design, setting, participants, details of index test and reference standard, and results in the form of numbers of participants given diagnoses of dementia or MCI. Data were also sought on dementia subtype diagnoses and on quantitative measures of patient or clinician satisfaction, resource use, costs and feasibility. We assessed risk of bias and applicability of each included study using QUADAS-2. We entered the results into 2x2 tables in order to calculate the sensitivity and specificity of telehealth assessment for the diagnosis of all-cause dementia, MCI, and any cognitive syndrome (combining dementia and MCI). We presented the results of included studies narratively because there were too few studies to derive summary estimates of sensitivity and specificity. MAIN
RESULTS: Three studies with 136 participants were eligible for inclusion. Two studies (20 and 100 participants) took place in community settings in Australia and one study (16 participants) was conducted in veterans' homes in the USA. Participants were referred from primary care with undiagnosed cognitive symptoms or were identified as being at high risk of having dementia on a screening test in the care homes. Dementia and MCI were target conditions in the larger study; the other studies targeted dementia diagnosis only. Only one small study used a 'pure' telehealth model, i.e. not involving any elements of face-to-face assessment. The studies were generally well-conducted. We considered two studies to be at high risk of incorporation bias because a substantial amount of information collected face-to-face by nurses was used to inform both index test and reference standard assessments. One study was at unclear risk of selection bias. For the diagnosis of all-cause dementia, sensitivity of telehealth assessment ranged from 0.80 to 1.00 and specificity from 0.80 to 1.00. We considered this to be very low-certainty evidence due to imprecision, inconsistency between studies and risk of bias. For the diagnosis of MCI, data were available from only one study (100 participants) giving a sensitivity of 0.71 (95% CI 0.54 to 0.84) and a specificity of 0.73 (95% CI 0.60 to 0.84). We considered this to be low-certainty evidence due to imprecision and risk of bias. For diagnosis of any cognitive syndrome (dementia or MCI), data from the same study gave a sensitivity of 0.97 (95% CI 0.91 to 0.99) and a specificity of 0.22 (95% CI 0.03 to 0.60). The majority of diagnostic disagreements concerned the distinction between MCI and dementia, occurring approximately equally in either direction. There was also a tendency for patients identified as cognitively healthy at face-to-face assessment to be diagnosed with MCI at telehealth assessment (but numbers were small). There were insufficient data to make any assessment of the accuracy of dementia subtype diagnosis. One study provided a small amount of data indicating a good level of clinician and especially patient satisfaction with the telehealth model. There were no data on resource use, costs or feasibility. AUTHORS'
CONCLUSIONS: We found only very few eligible studies with a small number of participants. An important difference between the studies providing data for the analyses was whether the target condition was dementia only (two studies) or dementia and MCI (one study). The data suggest that telehealth assessment may be highly sensitive and specific for the diagnosis of all-cause dementia when assessed against a reference standard of conventional face-to-face assessment, but the estimates are imprecise due to small sample sizes and between-study heterogeneity, and may apply mainly to telehealth models which incorporate a considerable amount of face-to-face contact with healthcare professionals other than the doctor responsible for making the diagnosis. For the diagnosis of MCI by telehealth assessment, best estimates of both sensitivity and specificity were somewhat lower, but were based on a single study. Errors occurred at the cognitively healthy/MCI and the MCI/dementia boundaries. However, there is no evidence that diagnostic disagreements were more frequent than would be expected due to the known variation between clinicians' opinions when assigning a dementia diagnosis.
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 34282852      PMCID: PMC8406800          DOI: 10.1002/14651858.CD013786.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  29 in total

1.  Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach.

Authors:  Haitao Chu; Stephen R Cole
Journal:  J Clin Epidemiol       Date:  2006-09-28       Impact factor: 6.437

2.  Associations with publication and assessing publication bias in dementia diagnostic test accuracy studies.

Authors:  Claire Wilson; Daniel Kerr; Anna Noel-Storr; Terence J Quinn
Journal:  Int J Geriatr Psychiatry       Date:  2015-03-17       Impact factor: 3.485

3.  DECIDE: a user friendly web-based service for early diagnosis and research on Alzheimer's disease.

Authors:  Fulvio Galeazzi; Federica Tanlongo; Valeria Ardizzone
Journal:  Stud Health Technol Inform       Date:  2012

4.  Videoconference diagnosis and management of Choctaw Indian dementia patients.

Authors:  Myron F Weiner; Heidi C Rossetti; Kasia Harrah
Journal:  Alzheimers Dement       Date:  2011-11       Impact factor: 21.566

5.  [Feasibility of a telemedicine support system for diagnosing dementia in primary care].

Authors:  Joan Vilalta-Franch; Josep Garre-Olmo; Secundino López-Pousa; Jordi Llinàs-Reglà; Laia Calvó-Perxas; Rafael Cubí-Montfort
Journal:  Rev Neurol       Date:  2012-09-01       Impact factor: 0.870

6.  Video-telemedicine in a memory disorders clinic: evaluation and management of rural elders with cognitive impairment.

Authors:  Cynthia Barton; Rebecca Morris; Johannes Rothlind; Kristine Yaffe
Journal:  Telemed J E Health       Date:  2011-10-24       Impact factor: 3.536

7.  A Multidisciplinary Model of Dementia Care in an Underserved Retirement Community, Made Possible by Telemedicine.

Authors:  Jason V Tso; Roxanna Farinpour; Helena C Chui; Collin Y Liu
Journal:  Front Neurol       Date:  2016-12-23       Impact factor: 4.003

8.  Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA.

Authors:  Suzanne C Freeman; Clareece R Kerby; Amit Patel; Nicola J Cooper; Terry Quinn; Alex J Sutton
Journal:  BMC Med Res Methodol       Date:  2019-04-18       Impact factor: 4.615

9.  Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment.

Authors:  Jenny McCleery; Julian Laverty; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2021-07-20

10.  Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study.

Authors:  W Annefloor van Enst; Eleanor Ochodo; Rob J P M Scholten; Lotty Hooft; Mariska M Leeflang
Journal:  BMC Med Res Methodol       Date:  2014-05-23       Impact factor: 4.615

View more
  2 in total

Review 1.  Diagnostic test accuracy of remote, multidomain cognitive assessment (telephone and video call) for dementia.

Authors:  Lucy C Beishon; Emma Elliott; Tuuli M Hietamies; Riona Mc Ardle; Aoife O'Mahony; Amy R Elliott; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2022-04-08

2.  Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment.

Authors:  Jenny McCleery; Julian Laverty; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2021-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.